Please provide your email address to receive an email when new articles are posted on . A Bay Area neurotechnology firm has announced the commercial release of a novel artificial intelligence-based ...
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...
Sustained, intensive therapy with two antiglutamatergic drugs is superior to standard aggressive treatment for postanoxic super-refractory status epilepticus (SRSE), new research suggests. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results